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Background: Severe mental illness (SMI), including schizophrenia, bipolar disorder and severe depression, is
responsible for a substantial proportion of disability in the population. This article describes the aims and design of
a research study that takes a novel approach to targeted prevention of SMI. It is based on the rationale that early
developmental antecedents to SMI are likely to be more malleable than fully developed mood or psychotic
disorders and that low-risk interventions targeting antecedents may reduce the risk of SMI.
Methods/Design: Families Overcoming Risks and Building Opportunities for Well-being (FORBOW) is an accelerated
cohort study that includes a large proportion of offspring of parents with SMI and embeds intervention trials in a
cohort multiple randomized controlled trial (cmRCT) design. Antecedents are conditions of the individual that are
distressing but not severely impairing, predict SMI with moderate-to-large effect sizes and precede the onset of
SMI by at least several years. FORBOW focuses on the following antecedents: affective lability, anxiety, psychotic-like
experiences, basic symptoms, sleep problems, somatic symptoms, cannabis use and cognitive delay. Enrolment
of offspring over a broad age range (0 to 21 years) will allow researchers to draw conclusions on a longer
developmental period from a study of shorter duration. Annual assessments cover a full range of psychopathology,
cognitive abilities, eligibility criteria for interventions and outcomes. Pre-emptive early interventions (PEI) will
include skill training for parents of younger children and courses in emotional well-being skills based on cognitive
behavioural therapy for older children and youth. A sample enriched for familial risk of SMI will enhance statistical
power for testing the efficacy of PEI.
Discussion: FORBOW offers a platform for efficient and unbiased testing of interventions selected according to best
available evidence. Since few differences exist between familial and ’sporadic’ SMI, the same interventions are likely
to be effective in the general population. Comparison of short-term efficacy of PEI on antecedents and the long
term efficacy for preventing the onset of SMI will provide an experimental test of the etiological role of antecedents
in the development of SMI.
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Severe mental illness (SMI), including schizophrenia, bi-
polar disorder and severe depression, is responsible for a
substantial proportion of disability in the population.
Current treatments may ameliorate the course of SMI,
but do not provide a cure. Therefore, prevention of SMI
is a public health priority. To date, early interventions
have focussed on the prodromal stage shortly preceding
the onset of SMI [1]. These interventions have had some
notable successes, including halving the short-term risk
of developing SMI with a purely psychological approach
[2]. However, relatively poor long-term functional out-
comes [3] suggest that interventions in the prodromal
stage may come too late to normalize the developmental
trajectory. Therefore, pre-emptive early interventions
(PEI) at earlier stages of development may need to be
considered [4]. Because the familial and environmental
risk factors for mood and psychotic disorders largely
overlap [5,6] and because early antecedents are less spe-
cific than prodrome [7], PEI may need to focus on
broader categories, such as SMI, rather than a specific
diagnosis.
PEI can be informed by what is known about SMI.
First, SMI runs in families and the risk varies with the
degree of biological relatedness to an affected individual.
The familial risk is partly diagnostically specific: a son or
daughter of a parent with schizophrenia will have ap-
proximately eight-fold increased risk of developing
schizophrenia, but also a two-fold increased risk of de-
veloping bipolar disorder or depression [8]. Overall, one
in three offspring of parents with SMI will develop a
major mood or psychotic disorder by early adulthood
[8]. Molecular genetic variants also largely overlap be-
tween mood and psychotic disorders [6,9,10]. Second,
SMI may be more predictable than previously thought.
Longitudinal studies of representative population co-
horts suggest that most cases of SMI are preceded by
earlier antecedents. Antecedents including delays in cog-
nitive development, affective lability, anxiety, sleep prob-
lems, psychotic-like experiences and basic symptoms are
detectable in childhood or adolescence, and predict the
onset of SMI 4 to 15 years later with substantial effect
sizes [11-15]. This means that many cases of SMI can be
predicted before the prodromal stage to enable targeted
PEI. Third, the genetic and neurodevelopmental risk fac-
tors for SMI are malleable [16,17]. A Finnish adoption
study found that high quality parenting reduced the risk
of psychosis in adopted offspring of biological mothers
with schizophrenia to a level comparable to adoptees
from mothers with no mental illness [18]. Longitudinal
neuroimaging studies show brain abnormalities in indi-
viduals at familial risk at age 6-to-14 years that
normalize by age 17 in those who do not develop early
onset SMI but persist in those affected with SMI [19,20].Taken together, these three areas of knowledge indicate
that the risk of SMI is measurable and modifiable in
childhood and adolescence.
We propose that antecedents in combination with
family history of SMI present an opportunity for devel-
oping and testing PEI at earlier stages of development
than current ‘early interventions’. The use of a sample
enriched for family history of SMI will increase statistical
power for testing interventions’ effects on SMI risk be-
cause of the high base risk of developing SMI [8]. The
incomplete penetrance of multiple weak genetic risk var-
iants means that familial and sporadic cases of SMI are
unlikely to be fundamentally different [21]. Therefore,
interventions developed in familial high-risk context are
likely to generalize to broader target populations. Ante-
cedents detected at earlier stages of development are
likely to be less specific and less impairing than pro-
drome or full-blown SMI [1,22]. Therefore, PEI may
have to target the risk of mental illness in general or
broader groupings like SMI rather than narrow diagnos-
tic categories [5,6]. Following the principles of staging
and proportionality of interventions to current degree of
problems [1,22], the most acceptable and practical PEI
will be interventions that carry low burden to partici-
pants, have very low risk of adverse effects, and are likely
to be beneficial irrespective of whether a given individual
was going to develop SMI or not. Even at the prodromal
stage, low-risk psychological interventions were at least
as effective as antipsychotic medication that carries a
high burden of adverse effects [2,23,24]. Another low-risk
intervention that has shown efficacy in the prodromal
stage is dietary supplementation with polyunsaturated
fatty acids [25]. Therefore, psychological interventions and
dietary supplements are likely to be among the most prac-
tical and acceptable PEI.
In this article we outline the design and methods of a
familial risk enriched cohort study that aims to test the
efficacy of PEI for preventing SMI.
Methods/Design
Aims
This study has two related aims:
1. Explore the role of selected psychopathological and
cognitive antecedents in the development of severe
mental illness.
2. Evaluate the efficacy of antecedent-focussed pre-emptive
early interventions in reducing psychopathology,
improving functioning and preventing SMI.
Design
Families Overcoming Risks and Building Opportunities
for Well-being (FORBOW) is an accelerated cohort
study enriched in familial risk for SMI. The cohort is
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controlled trials of PEI in a cohort multiple randomized
controlled trial (cmRCT) design (Figure 1) [26]. In a
cmRCT, participants entering the cohort provide consent
for their information to be used in the evaluation of inter-
ventions. Eligibility criteria and outcomes are assessed as
part of regular cohort follow-ups. Some eligible partici-
pants are randomly selected to be offered an intervention.
Those who are randomly selected for intervention are
approached with an offer of intervention and provide a
separate informed consent for the intervention only.
Those who are not randomly selected to be offered the
intervention do not need to sign a second consent since
they are providing all measures as part of their participa-
tion in the cohort study. This design is more pragmatic
than traditional randomized controlled trials since it mir-
rors the practice of offering a preventive intervention to
non-treatment seeking participants and saves the partici-
pants from the unnatural and possibly harmful effect of
being allocated to a control group after hearing about the
details of a potentially beneficial intervention. Over time,
cohort participants can be randomly selected for one or
more interventions. Selection for each intervention is in-
dependent, allowing researchers to examine effects of each
intervention independently as well as effects of sequentialFigure 1 Cohort-multiple randomized controlled trial design.interventions. The accelerated character means that par-
ticipants can enter the study at a range of ages and the co-
hort will allow drawing conclusions about a longer
developmental period over a shorter study duration, tak-
ing advantage of intra-individual continuities and inter-
individual differences [27-29]. Accelerated cohort is also
suitable for interventions, since the participants are grad-
ually moving through the age window of eligibility, opti-
mizing the use of therapeutic resources and allowing to
complete relatively large intervention studies with small
intervention teams.
In FORBOW, the regular assessments occur in 12
month intervals. At each follow-up, we collect measures
to assess the eligibility for intervention as well as pri-
mary and secondary outcomes. Separate teams assess
offspring and parents. The researchers who assess the
offspring are blind to the diagnosis of parents and vice
versa. In 2013, the FORBOW study was launched in a
single centre in Halifax, Nova Scotia. With inclusion of
additional centres, FORBOW is likely to become a
multi-centre study.
Focus on severe mental illness
Several lines of research suggest that study of mental ill-
ness should not be limited to one diagnostic category
Figure 2 Sample size requirements to detect the effect of
preventive intervention. On the y axis is the sample size required
to detect an effect of intervention as statistically significant with a
power of 80%. On the x axis is the hazard ratio reflecting how much
an intervention reduces the risk of severe mental illness. The two
plotted lines demonstrate the dependence of sample size requirements
on the risk of developing severe mental illness in the absence of an
intervention (base rate). In a high-risk population of offspring of
parents with severe mental illness (base rate 32%), the sample
size required is 2.5 times lower than in the general population
(base rate 13%).
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egories in less selected samples. Conditions that are clas-
sified as separate diagnoses share most genetic and
environmental risk factors [5,6,8]. In addition, the early
antecedents to mental illness may be less diagnosis-
specific and the most pragmatic aim is prevention of any
SMI rather than one specific disorder [1,22]. Therefore,
the primary focus of the FORBOW study is the broad
category of SMI. Our definition of SMI comprises major
psychotic and mood disorders that typically start in late
adolescence or early adulthood and reach a severity that
requires inpatient or intensive psychiatric care. We in-
clude in the definition of SMI all cases of schizophrenia,
schizoaffective disorder and bipolar disorder type I. We
include cases of major depressive disorder and bipolar
disorder type II if they fulfill two or more severity cri-
teria: (1) severity that requires hospital admission, (2) re-
currence (3 or more episodes within 10 years), (3)
chronicity (symptoms present for most days over two
years or longer with no remissions lasting 2 months or
longer), (4) psychotic symptoms or (5) a life-threatening
suicide attempt. These severity criteria are designed so
that cases of broadly defined disorders are included if
they reach the degree of severity implicit in the concept
of SMI.
Participants, inclusion and exclusion criteria
FORBOW enrolls offspring of parents with SMI (FHR,
family high-risk offspring), and offspring of healthy par-
ents matched on neighbourhood and demographic fac-
tors (CO, comparison offspring). FHR are recruited by
referrals from adult mental health services, by clinicians
who treat parents with SMI. The recruitment materials
emphasise that all biological children should be invited
to participate, irrespective of whether or not they live
with the biological parent and whether or not there are
any concerns about their mental health. In several men-
tal health services across Nova Scotia, a systematic re-
cruitment procedure is in place where all patients are
asked about the number and age of biological children
and patients with SMI and one or more biological chil-
dren in the eligible age range are referred to FORBOW.
Partnership with the Department of Community Ser-
vices, Nova Scotia, allows following up children who are
not in the care of their biological parents. CO are re-
cruited through two pathways: (1) acquaintance referrals,
targeting families living in the same neighbourhood and
having children of the same age as the FHR; (2) school
recruitment by approaching parents of children in the
same geographic areas where FHR are enrolled. Both
ways of recruitment are designed to obtain a sample of
CO who are similar to FHR offspring in terms of neigh-
bourhood, school and socioeconomic status. At the time
of writing, FORBOW is enrolling offspring between ages3 years and 21 years. A planned downward extension
(FORBOW-ELF, Early Life Focus) will include offspring
below age 3. All offspring continue to be followed up
until age 27, to cover the highest risk period for SMI on-
set. To maximize generalizability, FORBOW assumes
broad inclusion and minimal exclusion criteria. All bio-
logical offspring in the eligible age range can participate
in the study provided that at least one of their biological
parents is available for assessment and that the offspring
or their legal guardian provides a valid informed con-
sent. Multiple offspring from the same family can enrol.
Exclusion criteria are acquired brain injury or intellectual
disability of a degree that makes all or most assessments
invalid. Offspring with milder intellectual disability, autism
or attention-deficit hyperactivity disorder can participate,
but the range of assessments may be reduced, given their
attention, comprehension and communication abilities.
Biological parents and other caregivers are also FORBOW
participants.
Sample size and power calculation
It is our aim to halve the risk of SMI by providing PEIs.
The sample size required to detect such effects with ad-
equate statistical power depends on the base risk of de-
veloping SMI in the absence of intervention (Figure 2).
Based on a meta-analysis of published familial high-risk
studies, the risk that an offspring of a parent with SMI
develops a major mood or psychotic disorder by early
adulthood is 32%, compared to 13% in the general
Table 1 Antecedents to severe mental illness
Antecedent Intervention Age
(years)
Affective lability Parenting 4 to 9
Cognitive-behavioural skills 9 to 21
Anxiety Parenting 6 to 9
Cognitive-behavioural skills 9 to 21
Psychotic-like experiences Cognitive-behavioural skills 7 to 21
Dietary (polyunsaturated fatty acids) 7 to 21
Basic symptoms Cognitive-behavioural skills 9 to 21
Dietary (polyunsaturated fatty acids) 7 to 21
Cognitive delay Parenting, cognitive training 4 to 9
Dietary (polyunsaturated fatty acids) 4 to 21








Cannabis use Personality targeted cognitive-
behavioural intervention
11 to 21
Next to each antecedent, we list potential interventions and age range for
antecedent assessment and intervention.
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high-risk offspring reduces the sample size requirements
2.5-fold compared to general population samples. As-
suming a 3:1 ratio of FHR and CO, and a 15% attrition
on follow-up, a sample of 316 (158 receiving interven-
tion and 158 in a control arm) is required to detect an
effect of intervention that halves the risk of SMI as sta-
tistically significant (p < 0.05) in a survival analysis with
a power of 80%. Pilot data suggest that approximately
50% participants may be eligible for interventions.
Therefore, FORBOW aims to recruit 632 participants.
Antecedents
Definition of antecedents
We define antecedents as conditions of the individual,
that predict SMI and precede its onset by at least several
years. The requirement that antecedents are conditions
of the individual excludes external risk factors, such as
poverty, violence, childhood maltreatment, urban up-
bringing and exposure to toxins or infections. We select
antecedents that have robust evidence for predicting
SMI with a moderate to large effect size (risk ratio
greater than 2), so that intervention efforts are not di-
rected towards risk factors that have only a trivial effect
on risk. Antecedents are typically distressing for the in-
dividual or the family, motivating an intervention irre-
spective of whether they augur more severe problems or
not. Antecedents are typically not severely impairing and
occur before the individual has missed out on major de-
velopmental opportunities. The typical lag between an
antecedent and the onset of SMI can be inferred from
published cohort studies. The requirement that an ante-
cedent typically precedes the onset of SMI by at least sev-
eral years (operationalized as ≥4 years) is intended to
focus intervention efforts to earlier stages where the devel-
opmental trajectories can be influenced with a smaller in-
vestment to a greater effect [30,31]. Following this
definition, we reviewed the literature and selected ante-
cedents that are listed in Table 1 and described below.
Affective lability
Affective lability (AL) is the propensity to experience
strong and sudden changes in mood that are seen by
others as unpredictable [32,33]. AL, measured by self-
report, parent-report, momentary experience sampling
or in response to experimental provocation is increased
in individuals with bipolar disorder and in offspring of
parents with bipolar disorder [34-38]. Increased AL per-
sists in full remission and separates individuals with bi-
polar disorder from those with other diagnoses [36,37].
AL predicts development of bipolar disorder in pro-
spective studies [39-41]. Therefore, AL may be an ante-
cedent to bipolar disorder [36,37,42,43]. Increased AL
has also been reported in major depressive disorder [42].The minimal available data suggest that AL may also be
a feature of schizophrenia [44].
Anxiety
Anxiousness and anxiety disorders are common anteced-
ents to many types of mental illness [11,12,45-47]. The rate
of anxiety disorders is doubled among offspring of parents
with bipolar disorder or depression [8,11,41,48-52]. In
the context of family history, anxiety in childhood or
adolescence confers very high risk of bipolar disorder
and depression [11,48-50]. Anxiety disorders precede
the development of the first major episode of SMI by on
average eight years [11]. Anxiety disorders respond well
to cognitive behavioural therapy (CBT) [53,54]. The
combined evidence suggests that anxiety disorders may
represent a modifiable stage in the development of
mood disorders [11,41]. The relationship between anx-
iety and schizophrenia is less well understood. Some
evidence supports a continuum from anxiety to psych-
osis [55,56]. While population-based registry studies
suggest a familial association between anxiety disorders
and schizophrenia [57], a meta-analysis of family high
risk studies found sparse data and no evidence of asso-
ciation [8].
Psychotic-like experiences
While schizophrenia and other psychotic disorders typ-
ically onset in late adolescence or early adulthood, iso-
lated psychotic symptoms are frequently experienced in
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cinations and, in the absence of psychotic disorder, are
commonly referred to as ‘psychotic-like experiences’
(PLE). PLE are reported by 5% adults, 7.5% adolescents
and up to 17% children in the general population
[58-60]. Psychotic symptoms in childhood and adoles-
cence predict SMI in adulthood with moderately high
specificity [15,60-62]. Temporal course of PLE may be
important, with persistent PLE being more predictive of
SMI than transitory PLE [63-65]. Since childhood PLE
have overlapping aetiological factors with full-blown
psychosis [66], they can be conceptualized as anteced-
ents and represent a potential target for PEI. There is
evidence that PLE are more frequent in offspring of par-
ents with SMI [66], but PLE have not been systematically
evaluated in familial high-risk setting.
Basic symptoms
In addition to PLE, a second group of unusual experi-
ences predictive of SMI have been identified; the so
called basic symptoms (BS), which describe subjectively
perceived deficits and abnormalities in multiple domains
(perception, cognition, language, feelings) and often rep-
resent early manifestations of SMI. BS have been shown
to strongly and specifically predict the development of
schizophrenia 5-to-10 years later [13,67,68]. Since BS
precede SMI by at least several years and are distressing
and impairing in their own right, they represent a poten-
tial target for PEI. Indeed, a psychosocial intervention
targeting BS reduced the risk of developing SMI in a
clinical high-risk sample [69]. BS have not yet been eval-
uated in familial high-risk setting and it is unknown if
they are more common in offspring of parents with
schizophrenia or mood disorders.
Functional somatic symptoms
Functional somatic symptoms (FSS) include stomach
aches, headaches, eye problems and other physical com-
plaints with no known medical cause. FSS in childhood
have been found to predict adult depression more
strongly than childhood depressive symptoms. [70] FSS
are associated with familial risk for depression and bipo-
lar disorder and prospectively predict onset of major
mood disorders [71]. FSS also predict onset of psychotic
disorder among prodromal subjects [72]. These lines of
evidence converge to suggest that FSS may be relatively
early and nonspecific antecedents to multiple types of
SMI. FSS can be effectively targetted with CBT and
mindfulness-based interventions in adults [73,74] and in
children [75].
Sleep problems
Sleep problems are another common and nonspecific
predecessor for a range of mental and physical healthproblems. Sleep problems in childhood are prospectively
associated with a range of mental health problems in
adolescence and adulthood, including depression and bi-
polar disorder [11,76,77]. Sleep problems respond well
to brief CBT interventions [78]. Therefore, sleep prob-
lems may be an early and modifiable antecedent of SMI.
Cannabis use
Cannabis use is another potential target of early inter-
ventions. Regular use of cannabis in adolescence predicts
psychotic and mood disorders and deterioration of intel-
lectual functioning [79-81]. The use of cannabis and
other drugs can be effectively reduced through brief
cognitive-behavioural interventions targeted at individ-
ual temperamental risk factors for drug use [82].
Cognitive delay
Impaired cognitive function and delayed cognitive devel-
opment are important predictors of SMI [14,83-87]. The
predictive significance of cognitive ability may depend on
its development: while stably low cognitive ability predicts
a wide range of adult mental disorders [14,83,84,86], a
progressive decline below one’s projected trajectory may
be a relatively specific antecedent to schizophrenia [85,86].
The relationship between cognitive ability and bipolar
disorder is complex: while both poor and excellent cog-
nitive ability in childhood predicts bipolar disorder
[14,88,89], patients with bipolar disorder and their rela-
tives perform on average worse than controls on cogni-
tive tests [90-92]. Low cognitive performance predicts
psychosis among subjects at high clinical risk [93-99].
This prediction holds across most domains of cognitive
ability, but verbal learning and verbal memory show the
most robust effects [93,97,99].
Assessments
Separate research teams assess offspring and parents. Both
biological parents are assessed. Researchers assessing the
offspring are blind to the diagnosis of the parents and vice
versa. Parents and offspring are discouraged from discuss-
ing details of assessment with each other. All assessors are
blind to allocation to interventions and participants are
specifically instructed not to mention study intervention
to the assessors. Parents and offspring are assessed con-
currently to optimize the use of their time.
Parent assessment
We assess both biological parents for current and lifetime
mental illness with the Structured Interview for DSM-5
diagnoses (SCID-5) [100]. In addition to diagnoses, we col-
lect information on the age of onset, course and severity of
each disorder, medical illness, medication, demographic
variables and socioeconomic status. We assess family his-
tory of mental illness up to third degree relatives with
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[101]. We measure the current level of psychopathology
and well-being with the Everyday Feeling Questionnaire,
which enables self- and partner-report [102].
Offspring assessment
At baseline and annual follow-ups, we collect demo-
graphic information, information on risk factors, ante-
cedents to SMI, full range of psychopathology, cognitive
abilities, activities and quality of life. Questions on psy-
chopathology are balanced with positively phrased ques-
tions on free time activities and quality of life, to dilute
the negative focus of symptom-targeted questions. Initial
assessment covers the lifetime psychopathology and risk
factor exposures. Follow-up assessments focus on the 12
months period since the last assessment. The same as-
sessments are carried out in FHR and CO. Offspring as-
sessments are listed in Table 2 and described below.
Descriptive variables
We measure socioeconomic status as parent education,
occupation, wealth, income, area of residence, living ar-
rangements (rented/owner occupied; ratio of bedrooms
to persons) [103], and with the Family Affluence Scale
[104,105]. We also record the number of children in the
household, their sex and ages.
Psychopathology
We establish current and lifetime DSM-5 diagnoses in
the offspring with a semi-structured diagnostic inter-
view, the Kiddie Schedule for Affective Disorders and
Schizophrenia - Present and Lifetime version (K-SADS-
PL), adapted for DSM-5 [106,107], with best estimate
diagnoses established in consensus meetings involving
psychiatrists blind to the diagnoses of parents. Informa-
tion provided by parents and by the offspring is submit-
ted for these meetings after checking that it is free of
any indication of parental diagnosis or intervention
allocation. In offspring aged 18 or over, we use both
K-SADS (to cover childhood diagnoses retrospectively)
and SCID-5 at baseline and SCID-5 on follow-ups. For
each disorder, we establish the age at onset, course and
severity. In addition to diagnostic interviews, we obtain
self- and parent-report continuous measures of psycho-
pathology [108,109].
Functioning and quality of life
We measure quality of life with the Child Health Ques-
tionnaire (CHQ), parent- and young person report, in 5
- 18 year olds [110-112] and with the Quality of Life En-
joyment and Satisfaction Questionnaire-Short Form
(QOL) in adults (>18 years). We measure functional out-
comes using the Global functioning: Role and Social
scales [113], Columbia Impairment Scale (CIS), parentand youth report, and a list of developmental milestones
(school exams, driver’s licence, first summer job, …).
Affective lability
We assess AL with the child - and adult versions of the
Affective Lability Scales (ALS) [32,33,114]. The Child ALS
is rated by parents of 7 to 16 year olds [32]. The self-
report child version is used from age 12 and the adult ver-
sion from age 17 onwards [33,114]. Where more than one
measure is available from the same assessment (e.g. parent
and self-report), we consider the higher score unless there
is a reason to doubt the validity of the higher scoring in-
formant [115,116]. We define the antecedent ‘affective la-
bility’ as a score of 1 standard deviation or more above the
mean of a normative sample [38].
Anxiety
We assess anxiety disorders and symptoms with semi-
structured diagnostic interviews and dimensional measures.
We define the antecedent ‘anxiety’ as a diagnosis of an anx-
iety disorder (generalized anxiety disorder, social phobia,
agoraphobia, panic disorder, separation anxiety disorder,
specific phobia, obsessive compulsive disorder or posttrau-
matic stress disorder) with K-SADS or SCID-5, or a score
above the high-specificity cut-off (≥30) on the Screen for
Child Anxiety Related Emotional Disorders (SCARED)
[109]. In children below age 9, anxiety is defined as a score
1 standard deviation or more above a normative sample
on the parent-reported Spence Children Anxiety Scale
(S-CAS) [117]. Following the established standard in child
psychiatry, we consider anxiety present if reported by either
the parent or the child unless there is a reason to doubt the
veracity of a positive report [115,116,118,119].
Psychotic-like experiences
We measure PLE with several validated instruments. In
offspring aged 7 to 21 years, we use the ‘Funny feeling’
(FF) interview where the psychotic character of initial self-
report is corroborated with probes about the nature and
context of the experience [66,120]. We record frequency,
distress, impairment and appraisal (internal/external, sig-
nificant/not-significant) for each symptom. An independ-
ent clinical evaluator curates the verbatim transcription of
each unusual experience and rates its psychotic character
as none, probable or definite. Only PLE curated as ‘defin-
ite’ qualify as an antecedent. In addition, we assess psych-
otic symptoms with parent- and youth-report in the
K-SADS interview, consensus-rated by an independent
certified child and adolescent psychiatrist. In participants
aged 12 and more, we also assess psychotic symptoms
with the Structured Interview for Prodromal Symptoms
(SIPS) [121]. The antecedent PLE is present if one or more
symptoms are independently curated or clinician consensus-
confirmed as definitely psychotic.
Table 2 Offspring assessments
Domain Method Source Age
Descriptive variables
Demographics Questionnaire Parent 0-25
Socioeconomic status Questionnaire Parent 0-25
FAS Offspring 7-25
Height, weight, head &
waist circumference
Measurement Offspring 0-18
Pubertal status Questionnaire Offspring 9-16
Psychopathology
Diagnosis K-SADS Offspring 5-21
SCID-5 Offspring 18-25
General psychopathology CBCL Parent 5-15
CBCL-YSR Offspring 11-17
Personality risk factors SURPS Offspring 11-15




Substance use DUSI-R Offspring 9-25
Functional outcomes
General functioning CIS Rater 9 -
17
General, role and social
functioning
GAF, GF-R, GF-S Rater 11-25
Quality of life CHQ Parent 5 - 18
CHQ Offspring 9 - 18
QOL Offspring 18 -
25
Activities and milestones Questionnaire Parent 0 - 17
Offspring 9 - 25
Affective lability
Affective lability CALS-P Parent 5-16
Affective lability CALS-C Offspring 13-16





Anxiety (disorders) K-SADS/SADS-P Offspring 5-16
Anxiety (dimension) CBCL Parent 11-18
Anxiety (dimension) CBCL-YSR Offspring 3-5
Anxiety (dimension) S-CAS Parent 5-17
Anxiety (dimension) S-CAS Offspring 8-17
Anxiety (dimension) SCARED Parent 8-25
Anxiety (dimension) SCARED Offspring 8-25
Psychotic symptoms
Psychotic-like experiences Funny Feelings Offspring 7-18




Table 2 Offspring assessments (Continued)
Psychotic symptoms PANSS Offspring 14-25
Basic symptoms
Basic Symptoms SPI Offspring 6-25
Sleep






Somatic symptoms CBCL Parent 5-15
Somatic symptoms CBCL-YSR Offspring 11-17
Cognitive ability &
development
General cognitive ability WPPSI Offspring 3-5
WASI Offspring 6-25




Story recall (CMS) Offspring 16-25
Logical Memory (WMS) Offspring 8-25






Spatial working memory CANTAB Offspring 5-25





Emotional decision making CANTAB Offspring 8-25
Abbreviations: Abbreviations: FAS = Family Affluence Scale; K-SADS = Kiddie
Schedule for Affective Disorders and Schizophrenia SCID-5 Structured Clinical
Interview for DSM-5 Disorders; CBCL = Child Behaviour Checklist; CBCL-YSR =
Child Behaviour Checklist - Youth Self Report; SURPS = Substance Use Risk
Profile Scale; MFQ =Mood and Feelings Questionnaire; TOF = Test Observation
Form; DUSI-R – Drug Use Screening Inventory – Revised; CIS = Columbia
Impairment Scale; GF-R = Global Functioning: Role; GF-S = Global Functioning:
Social; GAF = Global Assessment of Functioning; CHQ = Child Health Question-
naire; QOL = Quality of Life Short Form; CALS = Child Affective Lability Scales;
ALS = Affective Lability Scales; SCAS = Spence Child Anxiety Scale; SCARED =
Screen for Child Anxiety Related Disorders; SIPS = Structured Interview for
Prodromal Symptoms; PANSS = Positive and negative Symptom Scale; SPI =
Schizophrenia Proneness Instrument; CSHQ = Children’s Sleep Habits
Questionnaire; SSR = Sleep Self Report; SSHS = School Sleep Habits Survey,
PSQI = Pittsburgh Sleep Quality Index; WPPSI = Wechsler Preschool and Primary
Scale of Intelligence, WASI = Wechsler Abbreviated Scale of Intelligence;
CVLT = California Verbal Learning Task; WMS =Wechsler Memory Scale; BVRT =
Benton Visual Retention Task; D-KEFS = Delis Kaplan Executive Functioning
System Verbal Fluency Index; COWAT = Controlled Oral Ward Association Test;
CANTAB = Cambridge Neuropsychological Test Automated Battery.
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We assess basic symptoms with the Schizophrenia Prone-
ness Instrument Child and Youth version. (SPI-CY)
[122,123]. We define the antecedent ‘basic symptoms’ as
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symptom profiles that were shown to predict schizophre-
nia with high specificity: Cognitive Perceptive basic symp-
toms (COPER) requiring a severity rating of 3 or more on
SPI-CY for one or more of the 10 most strongly predictive
cognitive or perceptual domain symptoms, or Cognitive
Disturbance (COGDIS) requiring 2 of 9 cognitive/percep-
tual symptoms scored 3 or higher, as recommended by the
measure authors [122,123].
Functional somatic symptoms
We measure FSS with the somatic subscale of the parent-
report Child Behavioural Checklist (CBCL) and the self-
report of the Youth Self Report (YSR) [108].
Sleep problems
We assess sleep problems with the parent-report Chil-
dren’s Sleep Habits Questionnaire (CSHQ) [124], and
several self-report measures for different age groups, in-
cluding the Sleep Self Report (SSR) [125], School Sleep
Habits Survey (SSHS) [124] and the Pittsburgh Sleep
Quality Index (PSQI) [126].
Cannabis use
We assess the frequency of cannabis and other drug use
with the self-report Drug Use Screening Inventory -
Revised (DUSI-R) [127] in addition to diagnostic interviews.
Cognitive delay
We assess both general cognitive ability and specific as-
pects of cognitions that are relevant to SMI. We list the
cognitive tests and applicable age in Table 2. We assess
general cognitive ability with the Wechsler Abbreviated
Scale of Intelligence, Second Edition (WASI-II), which
which contains four tests (vocabulary, block design, simi-
larities and matrix reasoning) and is normed to provide a
standardized full scale general cognitive ability score for
subjects from 6 years onwards [128]. In participants aged 3
to 5, we use the Wechsler Preschool and Primary Scale of
Intelligence (WPPSI-III), which is normed for ages 2.6-7.3
[129]. In addition, we include specific tests selected based
on their ability to discriminate individuals at high familial
or clinical risk for SMI from controls and predict onset
of SMI. These include attention and speed (digit-symbol
coding test DSCT subtest from the WPPSI, WISC-IV,
WAIS-IV), working memory (Letter Number Sequencing;
Digit Span backward subtests from the WISC-IV, WAIS-
IV), spatial working memory (CANTAB), verbal learning
and memory (California Verbal Learning Test - Children’s
Version, CVLT-C), logical memory (story recall from
Wechsler Memory Scale – Revised or Children’s Memory
Scale, LM), verbal fluency (Delis Kaplan Executive Func-
tioning System Verbal Fluency Index, D-KEFS; Controlled
Oral Word Association Test, COWAT), emotional decisionmaking (Cambridge Gambling Task (CGT), planning/
visuospatial organization in executive function (Rey-
Osterrieth Complex Figure, ROCF), and visuospatial
memory and organization (Benton Visual Retention Test
[BVRT]) [85,90,93-95,97-99,130-132]. Tests are adminis-
tered by master-level psychologists, trained and supervised
by doctoral-level clinical neuropsychologists. Where alter-
native forms are available (CVLT, COWAT, D-KEFS,
BVRT), they are alternated in a fixed order that is the
same in FHR and CO. We construct an overall standard-
ized score as a mean of standard scores from the adminis-
tered tests, providing a general measure of cognitive
ability weighted towards the cognitive domains that are
most predictive of SMI. We define cognitive impairment
as performance 1 standard deviation (corresponding to 15
points on a standardized scale) below age-appropriate
population norms. We define cognitive delay as a decline
of 2/3 standard deviation (corresponding to 10 points on a
standardized scale) or more against own trajectory esti-
mated from previous measurements.
Follow-up and retention of participants
The validity of longitudinal study results depends on re-
tention rates. We build on experience from cohort stud-
ies that achieved long-term retention rates over 90%
[11,79,120,133-139]. We employ strategies to minimize
attrition including regular friendly and non-stigmatising
contact (updates, newsletters and greeting cards), request-
ing multiple contact routes and repeated attempts to
contact hard-to-reach individuals [138]. We provide a
welcoming environment with seamless completion of
assessments without unnecessary hassle. We reimburse
participants for their time and we support their transport
costs. Our target is 90% retention over 3 years.
Interventions
We preferentially consider low-burden, low-risk inter-
ventions that are proportionate to the relatively mild
antecedent psychopathology and are likely to be accept-
able to a large proportion of non-treatment seeking par-
ticipants and their families. The primary focus is on
psychological and nutrition supplement interventions.
For children below the age of 9, the interventions will
primarily target parents and carers, with an optional
involvement of the child participant. Parent skill train-
ing has strong evidence for efficacy in conditions char-
acterized by affective lability and anxiety [54]. Parent
skills training can be combined with cognitive training
for children to address cognitive delay and attentional
problems. [140]
For youth aged 9 and above, the psychological interven-
tions will focus on the young individual, with optional
involvement of parents or carers. The first such interven-
tion will involve the youth learning skills for emotional
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lem solving, present moment focus, distress tolerance,
reality testing, activity scheduling, and healthy sleeping,
following the principles of CBT. The intervention is
modular and adapted to the individual through a combin-
ation of core and optional modules, potentially addressing
multiple antecedents [141]. There is evidence that CBT in
childhood and adolescence has long-term positive impact
on mental health [142].
Further psychological intervention may address tem-
peramental risk factors that put an individual at risk for
drug use and other risk taking behaviours. There is evi-
dence that such interventions have lasting effects on
multiple domains of mental health and well-being [82].
Another type of safe and potentially effective interven-
tions are dietary supplements, such as polyunsaturated
fatty acids, vitamin D and choline, which have evidence
for beneficial effects on neurodevelopment [25,143,144].
The selection and development of interventions are on-
going and will take into account the evolving evidence
base for safety and efficacy.
Outcome measures
The primary short-term outcome for intervention stud-
ies within FORBOW is the persistence of antecedents in
the assessments following the offer of intervention. The
primary long-term outcome is the development of SMI.
Secondary outcomes are dimensional measures of func-
tioning, distress, psychopathology and quality of life and
diagnosis of any mental disorder on follow-ups.
Data analysis strategy
The analysis of outcomes will follow the intention-to-treat
principle [145]. Effects of interventions on antecedent per-
sistence will be tested with lagged effect binomial regres-
sion models. Long-term effects of interventions on the
risk of SMI onset will be tested in proportional hazard sur-
vival models. Clustering of siblings within a family will be
accounted for by hierarchical random effects of individual
and (where more than one sibling from same family are
included) of family or estimation of standard errors robust
to clustering within families. Missing data on covariates
will be handled with multiple imputation [146], so that
missing covariates do not reduce the number of subjects
available for analyses. Missing data on primary outcomes
(antecedents) will not be imputed [147].
Discussion
Ethical aspects
FORBOW assessments involve safe established proce-
dures and participation in FORBOW does not limit
participants in accessing any type of care. However,
FORBOW includes psychiatric assessments and offers
of interventions to young individuals, who are notpresently seeking treatment. Therefore, it is essential to en-
sure confidentiality and minimize the risk of stigmatization
(including self-stigmatization). We collaborate with organi-
zations of people with lived experience of mental illness
and communication specialists in the area of mental health
to optimize acceptability and minimize risks. The inclusion
of control families from the general population and sensi-
tive communication ensure that participation in the study
is not associated with a ‘risk’ label. We ask all parents and
offspring who have the capacity to provide written consent
after the study procedures are explained and written infor-
mation is provided. We ask parents or guardians for written
authorization for participation of offspring who may not
have the capacity to provide consent. This includes consent
to access electronic health-care related data through linkage
with health card numbers, and consent to be contacted for
additional research studies, including studies of interven-
tions. We ask offspring who lack the capacity to provide
consent for a verbal assent and we only include them if
both consent and assent are provided.
We acknowledge that research diagnosis does not
equal the need for treatment and we do not actively pro-
vide feedback on diagnoses and test results. We handle
requests from participants or families for individual
feedback on case-to-case basis with involvement of a li-
censed psychiatrist. Any feedback respects confidential-
ity of individual participants: information provided by
offspring is not disclosed to parents unless such disclos-
ure is necessary to prevent significant harm. Diagnosis
of parents will not be disclosed to the offspring. The
study protocol has been approved by the Capital District
Health Authority Research Ethics Board, the IWK
Health Centre Research Ethics Board, health authorities
across Nova Scotia, and the Department of Community
Services, Nova Scotia, Canada.
Conclusion and directions
Through a combination of familial history and anteced-
ents, FORBOW provides an opportunity to bring early
intervention efforts into a younger age group compared
to interventions in prodromal stages of SMI. Indirect
evidence suggests that earlier interventions may have
greater beneficial influence. However, only the long-term
results of FORBOW and similar studies will provide the
definite answer on whether earlier is better. Thanks to
random selection of eligible individuals for interventions,
FORBOW will experimentally test the role of early ante-
cedents in the etiology of mental illness. Even with
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